We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report.
- Authors
Yuki Awanami; Makoto Fukuda; Yasunori Nonaka; Tsuyoshi Takashima; Keiichiro Matsumoto; Masatora Yamasaki; Motoaki Miyazono; Yuji Ikeda; Awanami, Yuki; Fukuda, Makoto; Nonaka, Yasunori; Takashima, Tsuyoshi; Matsumoto, Keiichiro; Yamasaki, Masatora; Miyazono, Motoaki; Ikeda, Yuji
- Abstract
<bold>Background: </bold>The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab is a low-density lipoprotein (LDL)-lowering drug with a new mechanism, which is currently available in Japan. Here, for the first time, we report the successful use of the PCSK9 inhibitor in a patient with refractory nephrotic syndrome.<bold>Case Presentation: </bold>A 61-year-old woman was diagnosed with minimal change-type nephrotic syndrome in October 2012. She received prednisolone (PSL) and cyclosporin A (CyA), but she experienced several cycles of relapse and remission and was hospitalized in May 2016 due to relapse. However, in spite of steroid pulse therapy and adrenocorticotropic hormone (ACTH) administration, her urinary protein level did not improve. We started her on evolocumab with the expectation of equivalent LDL-lowering effects as seen with LDL apheresis. After that, the LDL cholesterol level and UP/UC were concomitantly decreased, and the serum albumin was increased. This was maintained even when we reduced the PSL dose. This suggests that evolocumab clinically improves the nephrotic condition.<bold>Conclusion: </bold>No other report has described the use of evolocumab for nephrotic syndrome (NS) or its effect on similar nephrotic conditions. We believe that the findings presented here are unique and may be beneficial when treating similar cases.
- Subjects
SUBTILISINS; LOW density lipoproteins; NEPHROTIC syndrome; KIDNEY diseases; DISEASE relapse; DISEASE remission
- Publication
BMC Nephrology, 2017, Vol 18, p1
- ISSN
1471-2369
- Publication type
journal article
- DOI
10.1186/s12882-017-0644-0